Cardiovascular toxicities with pediatric tyrosine kinase inhibitor therapy: An analysis of adverse events reported to the Food and Drug Administration. Issue 2 (17th November 2022)

• Record Type: Journal Article
• Authors: Narayan, Hari K.; Sheline, Karyn; Wong, Victor; Kuo, Dennis; Choo, Sun; Yoon, Janet; Leger, Kasey; Kutty, Shelby; Fradley, Michael; Tremoulet, Adriana; Ky, Bonnie; Armenian, Saro; Guha, Avirup
• Is Part Of: Pediatric blood & cancer. Volume 70:Issue 2(2023)
• Page Start: n/a
• Page End: n/a
• Publication Date: 2022-11-17
• Subjects: cardiotoxicity -- hypertension -- pediatric cancer -- tyrosine kinase inhibitor; Tumors in children -- Periodicals; Blood -- Diseases -- Periodicals; Cancer in children -- Periodicals; 618.92
• DOI: 10.1002/pbc.30059
• Languages: English
• ISSNs: 1545-5009

Abstract

Abstract: We sought to examine cardiovascular toxicities associated with tyrosine kinase inhibitors in pediatrics. We examined 1624 pediatric adverse events with imatinib, dasatinib, sorafenib, pazopanib, crizotinib, and ruxolitinib reported to the Food and Drug Administration between January 1, 2015, and August 14, 2020. There were 102 cardiovascular event reports. Hypertension was the most commonly reported cardiovascular event and was most frequently associated with sorafenib and pazopanib. The presence of infection increased the reporting odds of cardiovascular events overall and specifically cardiac arrest, heart failure, and hypertension. These data provide early insight into cardiovascular toxicities with tyrosine kinase inhibitor use in pediatrics.